Literature DB >> 23544808

Comparison of oral Ibuprofen and intravenous indomethacin for the treatment of patent ductus arteriosus in extremely low birth weight infants.

Eun Mi Yang1, Eun Song Song, Young Youn Choi.   

Abstract

OBJECTIVE: There are few published reports concerning the efficacy of oral ibuprofen for the treatment of patent ductus arteriosus (PDA) in extremely low birth weight (ELBW) infants. Oral ibuprofen was compared to intravenous indomethacin regarding efficacy and safety in the treatment of PDA in infants weighting less than 1,000g at birth.
METHOD: This was a retrospective study in a single center. Data on ELBW infants who had an echocardiographically confirmed PDA were collected. The infants were treated with either intravenous indomethacin or oral ibuprofen. Rate of ductal closure, need for additional treatment, drug-related side effects or complications, and mortality were compared between the two treatment groups. RESULT: 26 infants who received indomethacin and 22 infants who received ibuprofen were studied. The overall rate of ductal closure was similar between the two treatments: it occurred in 23 of 26 infants (88.5%) treated with indomethacin, and in 18 of 22 infants (81.8%) treated with ibuprofen (p=0.40). The rate of surgical ligation (11.5% versus 18.2%; p=0.40) did not differ significantly between the two treatment groups. No significant difference was found in post-treatment serum creatinine concentrations between the two groups. There were no significant differences regarding additional side effects or complications.
CONCLUSION: In ELBW infants, oral ibuprofen is as efficacious as intravenous indomethacin for the treatment of PDA. There were no differences between the two drugs with respect to safety. Oral ibuprofen could be used as an alternative agent for the treatment of PDA in ELBW infants.
Copyright © 2013 Sociedade Brasileira de Pediatria. Published by Elsevier Editora Ltda. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23544808     DOI: 10.1016/j.jped.2013.02.006

Source DB:  PubMed          Journal:  J Pediatr (Rio J)        ISSN: 0021-7557            Impact factor:   2.197


  7 in total

1.  Comparative effectiveness and safety of indomethacin versus ibuprofen for the treatment of patent ductus arteriosus.

Authors:  Brian C Gulack; Matthew M Laughon; Reese H Clark; Meera N Sankar; Christoph P Hornik; P Brian Smith
Journal:  Early Hum Dev       Date:  2015-09-19       Impact factor: 2.079

2.  Ibuprofen Versus Indomethacin for Medical Closure of the Patent Arterial Duct: A Pooled Analysis by Route of Administration.

Authors:  Rohit Loomba; Karan Nijhawan
Journal:  Cureus       Date:  2015-06-04

3.  The Association between Patent Ductus Arteriosus and Perinatal Infection in A Group of Low Birth Weight Preterm Infants.

Authors:  Edmond Pistulli; Arjan Hamiti; Sokol Buba; Alketa Hoxha; Nita Kelmendi; Gentian Vyshka
Journal:  Iran J Pediatr       Date:  2013-11-22       Impact factor: 0.364

4.  Bedside surgery to treat patent ductus arteriosus in low-birth-weight premature infants.

Authors:  Gökhan Albayrak; Koray Aykut; Mustafa Karacelik; Ramazan Soylar; Kemal Karaarslan; Burçin Abud; Mehmet Guzeloglu; Eyup Hazan
Journal:  Open J Cardiovasc Surg       Date:  2014-08-17

5.  Oral paracetamol versus oral ibuprofen for treatment of patent ductus arteriosus.

Authors:  Manar Al-Lawama; Iyad Alammori; Tariq Abdelghani; Eman Badran
Journal:  J Int Med Res       Date:  2017-09-14       Impact factor: 1.671

6.  Oral ibuprofen is superior to oral paracetamol for patent ductus arteriosus in very low and extremely low birth weight infants.

Authors:  Jinmiao Lu; Qin Li; Lin Zhu; Chao Chen; Zhiping Li
Journal:  Medicine (Baltimore)       Date:  2019-08       Impact factor: 1.817

7.  The efficacy and safety of oral paracetamol versus oral ibuprofen for patent ductus arteriosus closure in preterm neonates - A systematic review and meta-analysis.

Authors:  Raymond Pranata; Emir Yonas; Rachel Vania; Radityo Prakoso
Journal:  Indian Heart J       Date:  2020-05-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.